Import from '@/components/mdx'

Can I Take Ginseng with Leqvio (Inclisiran)?

What Is Inclisiran (Leqvio) and Why Do Women Take It?

Inclisiran is a small-interfering RNA therapy that silences the gene encoding PCSK9 in the liver, reducing LDL-cholesterol by approximately 50 percent from baseline when added to maximally tolerated statin therapy. The ORION-11 trial demonstrated a 49.9 percent placebo-corrected LDL reduction at 510 days in adults with atherosclerotic cardiovascular disease (ASCVD) or high ASCVD risk. It is given as a 284 mg subcutaneous injection at day one, day 90, then every six months after that.

Women are not a small subset of this population. Cardiovascular disease is the leading cause of death for women in the United States, accounting for one in five female deaths annually. Yet women with ASCVD are still undertreated for LDL compared with men, and familial hypercholesterolemia (FH) affects roughly one in 250 people regardless of sex.

How Inclisiran Works Differently in Women

Sex-based pharmacokinetic differences in inclisiran are modest. Population PK modeling from the ORION program found that body weight, not sex per se, is the stronger covariate affecting drug exposure. Smaller average body size in women does produce slightly higher plasma concentrations at the same 284 mg fixed dose, but the FDA did not require a dose adjustment because the LDL response was consistent across sexes in pooled ORION trial data.

Women with heterozygous FH face a specific reproductive-years challenge: statins (the backbone therapy) are teratogenic, and now inclisiran adds its own pregnancy contraindication to the mix. This is covered in detail below.

Life-Stage Relevance

| Life Stage | Why Inclisiran May Come Up | |---|---| | Reproductive years | FH diagnosed in 20s-40s; contraception planning required | | PCOS | Dyslipidemia common; insulin resistance complicates glucose monitoring | | Perimenopause | Estrogen withdrawal raises LDL 10-15%; ASCVD risk climbs | | Post-menopause | Primary indication; largest treated population | | Postpartum | Statin restart timing; inclisiran avoid while breastfeeding |

What Is Ginseng and Why Do Women Take It?

Ginseng is not a single herb. Two species dominate the supplement market: Panax ginseng (Asian or Korean ginseng) and Panax quinquefolius (American ginseng). Both contain ginsenosides as their primary active compounds, but the ginsenoside profiles differ enough that their biological effects are not identical. A third product, Siberian "ginseng" (Eleutherococcus senticosus), is botanically unrelated and carries different interaction concerns.

Women reach for ginseng for several reasons. Perimenopausal women use it to address fatigue and cognitive fog. Women with PCOS use it for its purported insulin-sensitizing properties. Others take it for immune support, energy, or libido, a use for which the evidence is thin but not absent.

Ginseng is one of the most widely used herbal supplements globally, and a significant proportion of women do not tell their cardiologist or lipid specialist they are taking it. That omission matters when you are on a drug with the dosing interval of inclisiran.

The Interaction: Pharmacokinetic or Pharmacodynamic?

This distinction matters. A pharmacokinetic (PK) interaction changes how much drug reaches circulation: it alters absorption, distribution, metabolism, or excretion. A pharmacodynamic (PD) interaction leaves drug levels unchanged but amplifies or blunts the drug's effect through overlapping biology.

Is There a PK Interaction Between Ginseng and Inclisiran?

Almost certainly not in any clinically meaningful way. Inclisiran is metabolized by nucleases, not by cytochrome P450 enzymes. It does not rely on CYP3A4, CYP2C9, or P-glycoprotein, which are the most common targets of herb-drug PK interactions. Inclisiran's prescribing information lists no CYP-based interactions.

Ginseng does have some CYP-modulating activity. A 2012 study in healthy volunteers found that Panax ginseng modestly induced CYP3A4, but this would affect drugs like atorvastatin or cyclosporine, not inclisiran. So the PK risk here is effectively zero for the inclisiran molecule itself. The concern shifts entirely to the PD plane.

The Two Real Pharmacodynamic Concerns

Glucose lowering. Ginsenosides, particularly Rb1 and Rg1, activate AMPK pathways and improve insulin sensitivity. A randomized trial published in Archives of Internal Medicine found that 3 g of American ginseng taken before a glucose challenge significantly lowered postprandial glucose in people with type 2 diabetes and in healthy participants. The mean reduction was roughly 20 percent in the T2DM group.

Why does this matter for inclisiran users? Inclisiran itself does not directly alter glucose. But women who have ASCVD or FH often also have type 2 diabetes or are on insulin or sulfonylureas. Adding a supplement with documented glucose-lowering properties to an already managed blood sugar regimen raises the risk of hypoglycemia, particularly if you are fasting before a lipid panel or are postmenopausal with reduced glucagon counter-regulation.

Women with PCOS are a distinct subgroup to flag here. PCOS is characterized by insulin resistance, and many women with PCOS and early dyslipidemia may eventually be candidates for inclisiran if LDL remains elevated despite lifestyle and statin therapy. If you already take metformin or an SGLT2 inhibitor alongside ginseng, the glucose-lowering overlap can compound.

Anticoagulant potentiation. This is the more serious signal. Women with ASCVD are commonly prescribed aspirin, clopidogrel, or warfarin. Ginseng has demonstrated antiplatelet activity in vitro and in small human studies. A review in Pharmacognosy Review documented that ginsenosides inhibit platelet aggregation via thromboxane A2 suppression and nitric oxide modulation. The interaction with warfarin in particular has enough case reports and mechanistic data that the Natural Medicines database rates it as a "moderate" interaction warranting monitoring.

Inclisiran does not itself affect coagulation. The risk is that the woman on inclisiran is very likely also on aspirin or another antiplatelet drug, and ginseng's antiplatelet effect adds to that burden. This is a population-level pharmacodynamic interaction, not a direct inclisiran-ginseng one, but it lives inside the real clinical picture for most women who would be asking this question.

Evidence Gap: What We Do Not Know

WomanRx uses a three-tier framework to rate the quality of herb-drug interaction evidence in women's cardiovascular care:

Tier 1 (Direct evidence): Randomized trials in humans testing the specific drug-supplement pair. For inclisiran plus ginseng, there are zero Tier 1 studies. Inclisiran is still a young drug, approved in December 2021, and no formal interaction trial has been conducted.

Tier 2 (Mechanistic + analogue evidence): Known mechanism of the supplement, plus evidence from drugs with similar metabolism. The CYP data for ginseng is Tier 2 evidence that allows us to conclude PK interaction is unlikely for inclisiran. The glucose and antiplatelet data described above is Tier 2 evidence for PD concern.

Tier 3 (Extrapolation and case reports): Data from related supplements or case reports in similar populations. The warfarin-ginseng signal sits partly at Tier 2 and partly at Tier 3.

Women have historically been under-represented in cardiovascular pharmacology trials, and herb-drug interaction studies compound this problem: they often enroll predominantly healthy male volunteers. Every recommendation in this article is based on Tier 2 evidence at best. That does not mean the concern is theoretical; it means your prescriber should make the final call with your full medication list in hand.

Pregnancy and Lactation: What Every Woman Must Know

Inclisiran is contraindicated in pregnancy. The FDA label states that inclisiran may cause fetal harm based on animal reproductive toxicology data showing adverse developmental effects. There are no adequate or well-controlled studies in pregnant women. The prescribing information instructs clinicians to discontinue inclisiran if a patient becomes pregnant.

The dosing schedule creates a unique contraceptive planning challenge. Because inclisiran is given only twice a year, there is no daily pill to simply stop. The drug's biological effect on PCSK9 silencing persists for approximately six months after a dose. If you are planning a pregnancy, this timeline must be discussed with your cardiologist or lipid specialist well in advance, ideally at least 17 weeks before a planned conception attempt to allow the most recent injection's activity window to clear.

Women with FH who have been relying on a statin plus inclisiran for LDL control will need a comprehensive plan for the pregnancy interval. Statins must stop before conception. Inclisiran must stop. ACOG and the National Lipid Association recommend bile acid sequestrants such as cholestyramine as the only lipid-lowering option considered compatible with pregnancy, though they are not specifically approved for FH in pregnancy.

Lactation. It is not known whether inclisiran passes into human breast milk. Animal lactation data is absent from the public label. Given the uncertainty, the prescribing information advises against breastfeeding during treatment and for a period after the final dose. The half-life of inclisiran is approximately nine hours, but the PCSK9-silencing effect persists much longer, so the relevant washout period for lactation decisions is not the plasma half-life but the duration of pharmacodynamic activity.

What about ginseng in pregnancy? Ginseng should also be avoided in pregnancy. Ginsenoside Rb1 has demonstrated teratogenic effects in animal studies, and one human epidemiological study found an association between first-trimester ginseng use and increased birth defect risk, though the study was small and confounding was not fully controlled. The conservative guidance from most ob-gyns and from the American Pregnancy Association is to avoid all ginseng during pregnancy and breastfeeding.

If you are on inclisiran for FH and are also taking ginseng, the pregnancy planning conversation needs to address both.

Who This Is Right For, and Who Should Be Cautious

Women Who Can Likely Continue Ginseng with Close Monitoring

• Post-menopausal women on inclisiran who are not on warfarin, have no diabetes, and are not on antiplatelet therapy beyond low-dose aspirin.
• Women whose only lipid therapy is inclisiran plus lifestyle, with normal fasting glucose at baseline.
• Women who use ginseng seasonally, in low doses (500 to 1000 mg/day standardized extract), and have disclosed the use to their prescriber.

Even in this group, monitoring fasting glucose and reporting any unusual bruising to your clinician is a reasonable precaution.

Women Who Should Avoid Ginseng While on Inclisiran

• Women on warfarin or direct oral anticoagulants (DOACs) alongside inclisiran. The antiplatelet properties of ginseng may amplify bleeding risk from anticoagulation, even if the mechanism is different from DOAC action.
• Women with type 2 diabetes on insulin or sulfonylureas. Adding a glucose-lowering supplement to an already managed regimen introduces hypoglycemia risk.
• Women with PCOS on metformin and inclisiran. The glucose overlap, while usually modest, is unpredictable in individual patients.
• Perimenopausal women whose hormonal fluctuations already affect lipid and glucose metabolism unpredictably.
• Any woman within the six-month window after her most recent inclisiran injection who is planning to attempt conception.

Reproductive-Years Women with FH

If you are 25 to 40, have heterozygous FH, and were started on inclisiran because statins are not enough, your prescriber should also be managing your contraception plan. Effective contraception is required during inclisiran treatment. Women who are considering pregnancy within the next year should not start inclisiran. Those already on it need a clear stop date and a bridging lipid strategy documented in their chart.

Practical Guidance: What to Do Now

If you are already taking ginseng and you receive your inclisiran injection without having disclosed the supplement, here is what to do.

Tell your prescriber at your next visit, and bring the product label. Dose matters. A cup of ginseng tea contains far less ginsenoside than 3 grams of a standardized Korean red ginseng extract. The anticoagulant signal is dose-dependent, and the glucose-lowering effect seen in the 2000 Archives of Internal Medicine trial used 3 grams of American ginseng, which is higher than most commercial supplements.

Ask for a fasting lipid panel and fasting glucose at your six-month check-in. This is also when your next injection is typically due, so the appointment already exists in your schedule.

If you are on warfarin, ask your anticoagulation clinic for an INR check within four to six weeks of starting or stopping ginseng. Stopping ginseng abruptly can shift your INR just as starting it can.

The American Heart Association's scientific statement on complementary and alternative medicine in cardiovascular disease states plainly: "Patients should inform their physicians about all dietary supplements they are taking, as many have the potential to interact with cardiovascular medications." That statement was written before inclisiran existed, but the principle applies directly.

Dr. Maya Okafor, MD, WomanRx clinical reviewer, notes: "The real clinical gap here is not the inclisiran-ginseng pair itself, but the woman who is on aspirin, a statin, and now inclisiran, and also quietly taking three or four supplements her cardiologist does not know about. Getting the full supplement list at every injection visit is the single most useful intervention."

Monitoring Checklist for Women Taking Both

Use this as a guide for the conversation with your prescriber:

• Fasting glucose and HbA1c: At baseline before starting ginseng, then at the six-month injection visit.
• INR: If you take warfarin, within four to six weeks of any change in ginseng use.
• Anti-Xa level: If you take a low-molecular-weight heparin, though this is less commonly outpatient.
• LDL-C: Standard monitoring at each injection visit per the ORION follow-up protocol.
• Blood pressure: Some ginsenoside preparations modestly raise blood pressure at high doses; women with hypertension on inclisiran should track home readings.
• Symptom log: Note any unusual bruising, bleeding gums, or prolonged menstrual bleeding if you are in the perimenopause transition and still menstruating.

Injection site reactions are the most common adverse event with inclisiran, reported in approximately 8.2 percent of participants in ORION-11. These are not related to ginseng and should not be attributed to the supplement.